Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
WST 
West Pharmaceutical Services Inc (WST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: WST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $350.77
1 Year Target Price $350.77
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.99% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.95B USD | Price to earnings Ratio 41.13 | 1Y Target Price 350.77 |
Price to earnings Ratio 41.13 | 1Y Target Price 350.77 | ||
Volume (30-day avg) 13 | Beta 1.17 | 52 Weeks Range 186.94 - 347.77 | Updated Date 11/30/2025 |
52 Weeks Range 186.94 - 347.77 | Updated Date 11/30/2025 | ||
Dividends yield (FY) 0.30% | Basic EPS (TTM) 6.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.29% | Operating Margin (TTM) 21.85% |
Management Effectiveness
Return on Assets (TTM) 10.22% | Return on Equity (TTM) 16.95% |
Valuation
Trailing PE 41.13 | Forward PE 36.9 | Enterprise Value 19615410977 | Price to Sales(TTM) 6.61 |
Enterprise Value 19615410977 | Price to Sales(TTM) 6.61 | ||
Enterprise Value to Revenue 6.5 | Enterprise Value to EBITDA 25.5 | Shares Outstanding 71943412 | Shares Floating 71459952 |
Shares Outstanding 71943412 | Shares Floating 71459952 | ||
Percent Insiders 0.61 | Percent Institutions 97.84 |
Upturn AI SWOT
West Pharmaceutical Services Inc
Company Overview
History and Background
West Pharmaceutical Services, Inc. was founded in 1923. Initially focused on rubber products for pharmaceutical packaging, it has evolved into a global leader in innovative solutions for injectable drug delivery systems and services.
Core Business Areas
- Proprietary Products: Development and manufacture of stoppers, plungers, seals, and cartridges for injectable drug delivery. These products are primarily used for biologics, vaccines, and generic drugs.
- Contract-Manufactured Products: Production of complex drug delivery systems, including auto-injectors, pens, and inhalers, for pharmaceutical and biotech companies.
Leadership and Structure
Eric M. Green is the Chairman, President, and CEO. The company operates with a global structure, organized into regions and product-focused business units.
Top Products and Market Share
Key Offerings
- Elastomeric Closures: Rubber stoppers and plungers that provide a sterile barrier for injectable drugs. West is a leading player in this space. Competitors: Datwyler, SCHOTT Pharma.
- Self-Injection Systems: Auto-injectors and pens designed for patient self-administration of medications. Market competition: Bespak by Recipharm, Ypsomed.
- Daikyo Crystal Zenith: A cyclic olefin polymer (COP) that provides a high-purity, break-resistant alternative to glass for injectable drug packaging. Competition includes Gerresheimer.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery systems market is driven by the growth of biologics, biosimilars, and the increasing need for convenient drug administration. Trends include rising demand for pre-filled syringes, cartridges, and self-injection devices.
Positioning
West is a leader in the injectable drug delivery market, with a strong reputation for quality and innovation. Their focus on high-value products and services gives them a competitive advantage.
Total Addressable Market (TAM)
The global pharmaceutical packaging market is expected to reach approximately $150 billion by 2030. West is well-positioned to capture a significant portion of this market by providing innovative drug delivery components.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive product portfolio
- Global manufacturing and distribution network
- Focus on innovation and technology
- Established relationships with pharmaceutical companies
Weaknesses
- Exposure to raw material price fluctuations
- Dependence on a few large customers
- Potential for product recalls
- High capital expenditure requirements
Opportunities
- Growing demand for biologics and biosimilars
- Increasing adoption of self-injection devices
- Expansion into emerging markets
- Development of new drug delivery technologies
- Partnerships with pharmaceutical companies
Threats
- Competition from generic manufacturers
- Regulatory changes
- Economic downturns
- Technological obsolescence
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- Du00e4twyler Holding AG (DATW.SW)
- SCHOTT Pharma (Not Listed)
- Gerresheimer AG (GXI.DE)
Competitive Landscape
West Pharmaceutical Services maintains a competitive edge through innovation, strong customer relationships, and quality product offerings, while competitors focus on niche segments, regional markets or specific product applications.
Major Acquisitions
Evoqua Medical
- Year: 2023
- Acquisition Price (USD millions): 665
- Strategic Rationale: Enhanced West's portfolio in the medical device and delivery systems segment.
Growth Trajectory and Initiatives
Historical Growth: West has experienced consistent revenue growth, driven by demand for its proprietary products and contract manufacturing services.
Future Projections: Analysts project continued revenue growth, driven by the increasing demand for injectable drug delivery systems and the company's strong market position. Growth is projected to be at a rate of 6 to 9% per year.
Recent Initiatives: Recent initiatives include investments in capacity expansion, new product development, and strategic acquisitions to enhance its product portfolio and market reach.
Summary
West Pharmaceutical Services is a strong company with a leading position in the injectable drug delivery market. Their consistent revenue growth, driven by proprietary products and strategic acquisitions, indicates solid financial health. However, they need to monitor raw material prices and potential regulatory changes to mitigate risk. West is well-positioned to capitalize on the growing demand for biologics and self-injection devices, sustaining its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About West Pharmaceutical Services Inc
Exchange NYSE | Headquaters Exton, PA, United States | ||
IPO Launch date 1978-01-13 | Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.westpharma.com |
Full time employees 10600 | Website https://www.westpharma.com | ||
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.